Comparative Pharmacology
Head-to-head clinical analysis: FACTIVE versus GEMIFLOXACIN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTIVE versus GEMIFLOXACIN MESYLATE.
FACTIVE vs GEMIFLOXACIN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
320 mg orally once daily for 7-14 days
None Documented
None Documented
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic